X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/genprex-expands-clinical-trial-sites-for-acclaim-3-clinical-study-of-reqorsa-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302106790.html
https://www.fiercebiotech.com/biotech/gritstone-ground-down-phase-2-cancer-vaccine-fail-sparking-race-against-cash-gather-more
https://www.fiercepharma.com/pharma/bristol-myers-unfolds-subcutaneous-opdivo-data-kidney-cancer-i-o-battle-heads-new-front
https://endpts.com/roche-and-exelixis-detail-rare-success-for-cabometyx-tecentriq-combo-in-prostate-cancer/
https://www.pharmaceutical-technology.com/news/roche-tecentriq-sc-ec-approval/?cf-view
https://www.globenewswire.com//news-release/2023/12/11/2793678/0/en/Affimed-Announces-Positive-Data-for-AFM24-in-Combination-with-the-PD-L1-Checkpoint-Inhibitor-Atezolizumab-in-Heavily-Pre-treated-EGFR-Wildtype-Non-Small-Cell-Lung-Cancer-Patients.html
https://www.prnewswire.com/news-releases/oncolytics-announces-the-anal-cancer-cohort-of-the-goblet-phase-12-study-of-pelareorep-and-atezolizumab-has-met-the-success-criteria-for-efficacy-301983245.html
https://www.fiercepharma.com/pharma/roches-subcutaneous-tecentriq-hits-fda-delay-amid-manufacturing-process-changes
https://www.onclive.com/view/atezolizumab-plus-chemotherapy-demonstrates-intracranial-activity-in-advanced-nonsquamous-nsclc
https://www.reuters.com/world/uk/england-rollout-world-first-seven-minute-cancer-treatment-jab-2023-08-29/
https://www.prnewswire.com/news-releases/halozyme-announces-approval-of-roches-tecentriq-subcutaneous-sc-with-enhanze-in-great-britain-301911904.html
https://www.globenewswire.com//news-release/2023/08/23/2730093/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-provides-update-on-Phase-III-Skyscraper-01-study-in-PD-L1-high-metastatic-non-small-cell-lung-cancer.html
https://www.clinicaltrialsarena.com/news/tvardi-first-patients-liver-cancer/
https://www.onclive.com/view/venetoclax-atezolizumab-obinutuzumab-elicits-durable-responses-in-richter-transformation
https://www.fiercepharma.com/pharma/mercks-keytruda-trips-over-lung-cancer-subtype-roches-tecentriq-fails-kidney-cancer
https://www.fiercepharma.com/pharma/patient-deaths-taint-roches-industry-first-early-stage-liver-cancer-readout-tecentriq
https://www.globenewswire.com/news-release/2023/03/30/2637500/0/en/Omega-Therapeutics-Announces-Clinical-Supply-Agreement-to-Evaluate-the-Combination-of-OTX-2002-and-Atezolizumab-in-Hepatocellular-Carcinoma.html
https://www.fiercepharma.com/pharma/roche-exelixis-tecentriq-cabometyx-pair-fails-again-time-kidney-cancer
https://www.prnewswire.com/news-releases/carsgen-announces-collaboration-agreement-to-evaluate-ab011-in-combination-with-pd-l1-checkpoint-inhibitor-to-treat-gastric-cancer-301733205.html
https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-as-adjuvant-treatment-following-surgical-resection-and-platinum-based-chemotherapy-for-patients-with-stage-ib-t2a-%E2%89%A54-centimeters-ii-or-iiia-non/
https://www.biopharmadive.com/news/roche-tecentriq-avastin-adjuvant-liver-cancer-phase-3/640755/
https://www.pharmafile.com/news/744974/rare-cancer-drug-young-patients-approved
https://www.globenewswire.com/news-release/2022/12/16/2575333/0/en/Adagene-Announces-Clinical-Trial-Collaboration-to-Evaluate-Anti-CTLA-4-SAFEbody-ADG126-in-Combination-with-Roche-s-Standard-of-Care-for-First-Line-Advanced-Liver-Cancer.html
https://endpts.com/roche-wins-earlier-than-expected-approval-for-blockbuster-tecentriq-in-rare-soft-tissue-cancer/
https://www.biospace.com/article/exelixis-roche-combo-fails-to-improve-overall-survival-in-nsclc-/
https://www.globenewswire.com//news-release/2022/12/07/2569082/0/en/Replimune-Enters-into-Clinical-Collaboration-Agreement-with-Roche-for-the-Development-of-RP3-In-Colorectal-Cancer-and-Hepatocellular-Carcinoma.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034
https://www.fiercepharma.com/pharma/roche-having-shared-data-regulators-unwraps-results-subcutaneous-tecentriq-phase-3-trial
https://www.fiercepharma.com/pharma/roche-pulls-back-another-fda-accelerated-approval-cancer-drug-tecentriq
https://www.clinicaltrialsarena.com/news/attralus-par-therapy-trial/
https://www.fiercepharma.com/pharma/racing-merck-and-pfizer-roche-readies-file-subcutaneous-tecentriq-after-posting-phase-3-data
https://endpts.com/roche-trims-out-some-pipeline-failures-while-flagging-a-phiii-flop-for-tecentriq/
https://www.globenewswire.com/news-release/2022/06/16/2463894/0/en/Galecto-Announces-First-Patient-Enrolled-in-Phase-2-Trial-of-GB1211-in-Combination-with-Atezolizumab-for-First-Line-Treatment-of-NSCLC.html
https://www.prnewswire.com/news-releases/imaginab-and-roche-have-entered-a-clinical-trial-supply-agreement-for-provision-of-atezolizumab-tecentriq1-to-non-small-cell-lung-cancer-patients-enrolled-in-imaginabs-ipredict-phase-iib-study-301563288.html
https://www.europeanpharmaceuticalreview.com/news/172008/biontech-results-inest-pdac-treatment/
https://www.fiercebiotech.com/biotech/tigit-or-not-tigit-roches-latest-trial-flop-has-implications-big-pharmas-big-bet
https://www.reuters.com/business/healthcare-pharmaceuticals/roches-late-stage-trial-two-lung-cancer-drugs-fails-2022-05-11/
https://www.trialsitenews.com/a/genentechs-phase-3-skyscraper-01-study-fails-to-meet-endpoints-in-patients-with-pd-l1-high-metastatic-nsclc-71cbeb3d
https://www.biospectrumasia.com/news/26/20265/singapore-based-aum-biosciences-partners-with-roche-for-cancer-drug-trial.html
https://www.globenewswire.com/news-release/2022/05/09/2438532/0/en/Imago-BioSciences-Announces-First-Participant-Dosed-in-Investigator-Sponsored-Study-of-Bomedemstat-in-Combination-with-Atezolizumab-in-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2022/05/09/2438179/0/en/Nykode-Therapeutics-announces-positive-interim-results-from-its-Phase-2-trial-with-VB10-16-in-combination-with-immune-checkpoint-inhibitor-atezolizumab-in-advanced-cervical-cancer.html
https://seekingalpha.com/news/3825821-ema-panel-recommends-extending-indication-for-roches-cancer-therapy-tecentriq
Market Place
Share 
